drugset
drugset / Trial / NCT00790790

A Study in the Treatment of Osteoarthritis Knee Pain

NCT00790790 ↗

Phase 2 Completed 147 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To gather data on whether a new drug for osteoarthritis knee pain will be safe and have an effect on pain levels.

Timeline

Start
2008-11
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DASOLAMPANEL ETIBUTIL Small molecule 49 mg Oral
Subject DASOLAMPANEL ETIBUTIL Small molecule 105 mg Oral

Indications

osteoarthritis, knee